candesartan has been researched along with Bile Duct Obstruction in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan was withdrawn, with a progressive improvement in cholestasis and complete normalization of liver biochemistry at 6 months." | 5.56 | Candesartan-induced cholestatic hepatitis: a case report. ( García López, R; Hermida Pérez, B; Izquierdo Romero, M, 2020) |
| "Candesartan was withdrawn, with a progressive improvement in cholestasis and complete normalization of liver biochemistry at 6 months." | 1.56 | Candesartan-induced cholestatic hepatitis: a case report. ( García López, R; Hermida Pérez, B; Izquierdo Romero, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hermida Pérez, B | 1 |
| Izquierdo Romero, M | 1 |
| García López, R | 1 |
| Fukuda, H | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
2 other studies available for candesartan and Bile Duct Obstruction
| Article | Year |
|---|---|
Candesartan-induced cholestatic hepatitis: a case report.
Topics: Benzimidazoles; Biphenyl Compounds; Chemical and Drug Induced Liver Injury; Cholestasis; Hepatitis; | 2020 |
More relevant prediction for in vivo drug interaction of candesartan cilexetil on hepatic bile acid transporter BSEP using sandwich-cultured hepatocytes.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Benzimi | 2014 |